All 57
Interim results from the EQUATE Study: Preliminary safety and efficacy of itolizumab, a novel targeted anti-CD6 therapy, in newly diagnosed severe acute graft-versus-host disease
John Koreth, et. al., 2021
European Hematology Association (EHA) Virtual Congress 2021
06/10/2021/by David AndersonEuropean Hematology Association (EHA) Virtual Congress 2021
Validation of a Whole Blood and Proteomic Stabilized Blood Assay to Monitor the Engagement and Modulation of CD6 on T cells by Itolizumab as a Clinical Pharmacodynamic Biomarker in Autoimmune Diseases
Lynn Kisselbach, et. al., 2021
CYTO Virtual Interactive Meeting 2021
06/10/2021/by David AndersonCYTO Virtual Interactive Meeting 2021
Blockade of the CD6-ALCAM pathway modulates effector T cell function
Jeanette Ampudia, et. al., 2021
American Association of Immunologists (AAI) Annual Meeting 2021
05/14/2021/by eallisonAmerican Association of Immunologists (AAI) Annual Meeting 2021
Itolizumab-induced Antigenic Modulation of CD6 Inhibits T Cell Activity
Dalena Chu, et. al., 2021
American Association of Immunologists (AAI) Annual Meeting 2021
05/10/2021/by eallisonAmerican Association of Immunologists (AAI) Annual Meeting 2021
An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab
Angelina Bisconte, et. al., 2021
American Association of Immunologists (AAI) Annual Meeting 2021
05/10/2021/by eallisonAmerican Association of Immunologists (AAI) Annual Meeting 2021
Preliminary safety and efficacy of itolizumab, a novel targeted anti-cd6 therapy, in newly diagnosed severe acute graft-versus-host disease: interim results from the equate study
John Koreth, et. al., 2021
European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2021
03/12/2021/by eallisonEuropean Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2021
Early reconstitution of cd6+ t cells after hematopoietic cell transplantation identifies a suitable target for acute graft-versus-host disease treatment using anti-cd6 monoclonal antibody itolizumab
Benedetta Rambaldi et. al., 2021
European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2021
03/12/2021/by eallisonEuropean Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2021
Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate Study
John Koreth et. al., 2021
TCT Meetings Digital Experience 2021
02/10/2021/by eallisonTCT Meetings Digital Experience 2021
Impact of Itolizumab on the Expression of CD6 and the Function of Effector T Cells
Jeanette Ampudia et. al., 2020
American Society of Hematology Annual Meeting December 2020
12/05/2020/by David AndersonAmerican Society of Hematology Annual Meeting December 2020
Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab
Benedetta Rambaldi et. al., 2020
American Society of Hematology Annual Meeting December 2020
12/05/2020/by David AndersonAmerican Society of Hematology Annual Meeting December 2020
CD6-ALCAM Pathway is Elevated in Patients with Severe Asthma
Manali Mukherjee et. al., 2020
European Respiratory Society International Congress September 2020
09/18/2020/by eallisonEuropean Respiratory Society International Congress September 2020
CD6 Is Highly Expressed In Fatal Asthma Patients and May Modulate Bronchomotor Tone
Cynthia J. Koziol-White et. al., 2020
European Respiratory Society International Congress September 2020
09/18/2020/by eallisonEuropean Respiratory Society International Congress September 2020
CD6 Is Expressed On Human Airway and Blood ILCs and Is Upregulated by Epithelial Alarmins IL-33 and TSLP
Jana Badrani et. al., 2020
European Respiratory Society International Congress September 2020
09/18/2020/by eallisonEuropean Respiratory Society International Congress September 2020
CD6-ALCAM Signaling Regulates Multiple Effector/Memory T Cell Functions
Jeanette Ampudia et. al., 2020
American Association for Immunologists Conference May 2020
09/18/2020/by eallisonAmerican Association for Immunologists Conference May 2020
CD6 Modulation Ameliorates Immune Complex-Mediated Glomerulonephritis
Samantha A. Chalmers et. al., 2020
American Association for Immunologists Conference May 2020
09/18/2020/by eallisonAmerican Association for Immunologists Conference May 2020
Amelioration of Skin and Kidney Disease in a Spontaneous Murine Lupus Model via CD6 Modulation
Samantha A. Chalmers et. al., 2020
American Association for Immunologists Conference May 2020
09/18/2020/by eallisonAmerican Association for Immunologists Conference May 2020
Targeting the CD6-ALCAM Pathway to Prevent and Treat Graft vs Host Disease
Cherie Ng et. al., 2020
Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy & the Center for International Blood & Marrow Transplant Research February 2020
09/18/2020/by eallisonTransplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy & the Center for International Blood & Marrow Transplant Research February 2020
Itolizumab May Have Broad Therapeutic Potential
Krishna Polu, M.D.
Chief Medical Officer
2020
01/23/2020/by eallisonChief Medical Officer
2020
The Role of T Cells in Health and Disease
Stephen Connelly, Ph.D.
Chief Scientific Officer
2020
01/21/2020/by David AndersonChief Scientific Officer
2020
The Role of CD6-ALCAM Signaling in Autoimmunity
Stephen Connelly, Ph.D.
Chief Scientific Officer
2020
01/16/2020/by David AndersonChief Scientific Officer
2020
The CD6-ALCAM Pathway Maybe a Predictive Biomarker in Patients with Lupus Nephritis
Krishna Polu, M.D.
Chief Medical Officer
2020
01/21/2020/by David AndersonChief Medical Officer
2020
What Would You Say to an Individual Who is Newly Diagnosed with Lupus
Ellen H.
Lupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
01/21/2020/by David AndersonLupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
The Pathogenesis of Lupus
Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/21/2020/by David AndersonProfessor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
Itolizumab Uniquely Modulates Both the Activity and Trafficking of T Effector Cells
Krishna Polu, M.D.
Chief Scientific Officer
2020
01/21/2020/by David AndersonChief Scientific Officer
2020
Lupus is a Highly Heterogeneous Disease, No Two Patients Are Alike
Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/21/2020/by David AndersonProfessor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
The Need For a Personalized Approach in Treating Lupus Nephritis
Krishna Polu, M.D.
Chief Medical Officer
2020
01/21/2020/by David AndersonChief Medical Officer
2020
The Path to Diagnosis and the Journey of Lupus
Ellen H.
Lupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
01/21/2020/by David AndersonLupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
The Importance of Participating in Clinical Trials
Ellen H.
Lupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
01/16/2020/by David AndersonLupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
Why it’s Important to Consider Clinical Trial Participation
Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/16/2020/by David AndersonProfessor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
Working Towards a Brighter Future for Individuals with Lupus and Lupus Nephritis
Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/16/2020/by David AndersonProfessor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
What is the Current Treatment Approach for Patients with Lupus Nephritis?
Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/16/2020/by David AndersonProfessor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
The Clinical Implications of Lupus Nephritis
Krishna Polu, M.D.
Chief Medical Officer
2020
12/19/2019/by David AndersonChief Medical Officer
2020
EQUATE, a Phase 1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of a novel targeted anti-CD6 therapy, itolizumab, in subjects with newly diagnosed acute graft versus host disease
John Koreth et. al., 2019
American Society of Hematology Annual Meeting December 2019
09/18/2020/by eallisonAmerican Society of Hematology Annual Meeting December 2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation After In Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Benedetta Rambaldi, MD et. al., 2019
American Society of Hematology Annual Meeting December 2019
09/18/2020/by eallisonAmerican Society of Hematology Annual Meeting December 2019
Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease
Ng et al., 2019. Blood, 134:5603
12/30/2019/by David AndersonAmelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Samantha A. Chalmers et. al., 2019
American College of Rheumatology Annual Meeting November 2019
09/18/2020/by eallisonAmerican College of Rheumatology Annual Meeting November 2019
CD6 Inhibition Prevents Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Samantha A. Chalmers et. al., 2019
American College of Rheumatology Annual Meeting November 2019
09/18/2020/by eallisonAmerican College of Rheumatology Annual Meeting November 2019
Clinical and experimental evidence for targeting CD6 in immune-based disorders
Consuerga-Fernandez et al., 2018. Autoimmune Rev.
12/30/2019/by eallisonActivated leucocyte cell adhesion molecule (ALCAM/CD166) regulates T cell responses in a murine model of food allergy
Kim et al., 2018 192: 151-164.
12/30/2019/by eallisonActivated Leukocyte Cell Adhesion Molecule Stimulates the T-Cell Response in Allergic Asthma
Kim et al., 2018. American Journal of Respiratory and Critical Care Medicine. 197(8)
12/30/2019/by eallisonFailure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation
Meyer & Kofler, 2018. Cellular and Molecular Immunology.
12/30/2019/by eallisonThe role of CD6 in autoimmune diseases
Fox, 2018. Cellular & Molecular Immunology.
12/30/2019/by eallisonT cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
Bughani et al., 2018. PLoS One. 12(7): e0180088
12/30/2019/by eallisonCD6 as a potential target for treating multiple sclerosis
Li et al, 2017. PNAS. 114(10): 2687-2692.
12/30/2019/by eallisonTargeting CD6 for the treatment of experimental autoimmune uveitis
Zhang et al., 2017. Journal of Autoimmunity.
12/30/2019/by eallisonT Cell Costimulation by CD6 is Dependent on Bivalent Binding of a GADS/SLP-76 Complex
Breuning & Brown, 2017. Molecular and Cellular Biology.
12/30/2019/by eallisonGenetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis
Consuerga-Fernandez et al., 2017. Cellular and Molecular Immunology. 14: 1-9.
12/30/2019/by eallisonRelevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance
Consuerga-Fernandez et al., 2017. Frontiers in Immunology.
12/30/2019/by eallisonCD6 modulates thymocyte selection and peripheral T cell Homeostasis
Orta-Mascar et al., 2016. Journal of Experimental Medicine. 213(8): 1387-1397.
12/30/2019/by eallisonItolizumab – a humanized, anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
Roshni & Brinda, 2015. Clinical, Cosmetic and Investigational Dermatology. 8: 215-222.
12/30/2019/by eallisonHuman Treg cells are characterized by low/negative CD6 expression
Garcia Santana et al., 2014. Cytrometry A. 85(10): 901-908.
12/30/2019/by eallisonEfficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind randomized, placebo-controlled, phase-III study
Krupashnkar et al., 2014. J Am Acad Dermatol. 71(3): 484-492.
12/30/2019/by eallisonA common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation
Khatri et al., 2013 The Journal of Experimental Medicine 210 (11) 2205-2221
12/30/2019/by eallisonCD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction
Nair et al., 2010 Clinical and Experimental Immunology. 162: 116–130
12/30/2019/by eallisonLong-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells
Zimmerman et al., 2006. Blood 107(8): 3212-3220.
12/30/2019/by eallisonRelevance of CD6-mediated interactions in T cell activation and proliferation
Gimferrer et al., 2004. J Immunol 173(4): 2262-2270.
12/30/2019/by eallisonPrevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow
Soiffer et al., 1992. J Clin Oncol 10(7): 1191-1200.
12/30/2019/by eallison